Search

Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Resectable Head and Neck Cancer

NICE has published final technology appraisal guidance TA1145 recommending pembrolizumab (Keytruda) for the neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma in adults. The guidance includes a commercial access agreement with NHS pricing arrangements. NHS commissioners and providers are expected to fund the treatment in accordance with NICE recommendations.

Oregon PDAB Community Forums on Prescription Drug Costs

The Oregon Prescription Drug Affordability Board is hosting community forums in April and May 2026 to gather public input on prescription drug costs and their impact on Oregonians. Forums will be held both online and in-person across Oregon cities. The board will review eight medications including Jardiance, Ozempic, Keytruda, and others for affordability challenges.